Haemonetics is trading 4.1% up at $83.16 as the stock outperforms the broader market amid a strong move across healthcare peers.
- There are no fresh company-specific headlines, earnings, or analyst calls dated July 28, 2026, tied directly to the advance.
- The move appears primarily driven by bullish sentiment and institutional buying within the healthcare sector rather than a new company-specific catalyst.